USPTO trademark

LYMZENTY

Under examinationUSPTOWord markClass 5

"LYMZENTY" is a word mark owned by Celgene Corporation, filed at the USPTO on March 6, 2024. It is under examination and covers class 5 (Pharmaceuticals).

View Celgene Corporation portfolioGet this data via the API
Official USPTO record
LYMZENTY trademark as filed
As filed with the USPTO
Status
Under examination
Since September 15, 2026
Filed
March 6, 2024
Registered
Not yet
Expires
Not recorded
Application no.
98435992
Registration no.
Not yet
Office
USPTO
United States Patent and Trademark Office
Mark type
Word mark
1 class
Ownership

Who owns LYMZENTY

The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.

Owner

Celgene Corporation

Princeton, United States

3,125 trademarks in the portfolioView company

Representative

Marilyn F. Kelly

Bristol-Myers Squibb Company

Goods and services

What the mark covers

The products and services LYMZENTY is filed for, grouped by Nice class.

  • Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressant preparations, pharmaceutical antibodies for medical use, and immunotherapy preparations for the treatment of cancer; cytokine inhibitory drugs being pharmaceutical preparations for the treatment of cancer; anticoagulants; Pharmaceutical preparations for human use that modulate the immune system for the treatment of immune-system related diseases and disorders; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy for the treatment of cancer; Pharmaceutical and biological preparations for human use, namely, stem cells for medical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; Pharmaceutical preparations for human use for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for human use for the treatment of cancer and solid tumors; Pharmaceutical preparations for human use for the treatment of cystic fibrosis

History

What has happened so far

Steps recorded by the USPTO, newest first.

  1. Sou extension received with teas petition
  2. Notice of revival - e-mailed
  3. Petition to revive-granted
  4. Teas petition to revive received
  5. Abandonment notice e-mailed - no use statement filed
  6. Abandonment - no use statement filed
  7. Teas change of correspondence received
  8. Attorney/dom.rep.revoked and/or appointed
  9. Teas revoke/app/change addr of atty/dom rep received
  10. Noa e-mailed - sou required from applicant

10 earlier steps on the official record.

Disputes

Oppositions and cancellations

Proceedings recorded against this mark by the USPTO. Reported as recorded, not legal advice.

FAQ

About LYMZENTY

Who owns the trademark "LYMZENTY"?

The USPTO trademark "LYMZENTY" (application 98435992) is owned by Celgene Corporation.

What is the status of "LYMZENTY"?

Its status at the USPTO is: under examination.

API

Get this data via the API

Everything on this page comes from the Signa API. Pull LYMZENTY and marks like it into your own product with one request.

  • GET/v1/trademarks/{id}

    The full record: owners, classes, dates and images

  • GET/v1/trademarks/{id}/events

    Every step in the office history

  • GET/v1/proceedings?trademark_id={id}

    Oppositions and cancellations against the mark

Get API keyView docs
GET /v1/trademarks/{id}
ID=tm_019d2caa-a29d-7118-9e52-f1021630427c
curl https://api.signa.so/v1/trademarks/$ID \
  -H "Authorization: Bearer $SIGNA_API_KEY"
Response
{
  "id": "tm_019d2caa-a29d-7118-9e52-f1021630427c",
  "object": "trademark",
  "mark_text": "LYMZENTY",
  "status": {
    "primary": "pending",
    "stage": "examining"
  },
  "office_code": "US",
  "application_number": "98435992",
  "filing_date": "2024-03-06",
  "nice_classes": [
    5
  ],
  "owners": [
    {
      "name": "Celgene Corporation",
      "entity_id": "ent_019eb711-777f-75d6-b417-ae036199452c"
    }
  ]
}